# EDGAR Filing Document

**Accession Number:** 0002040475
**File Stem:** 0001213900-26-029050
**Filing Date:** 2026-3
**Character Count:** 20587
**Document Hash:** 7e7a605ef7ed855f7d4c7a284f7937f2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-029050.hdr.sgml**: 20260317

**ACCESSION NUMBER**: 0001213900-26-029050

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260311

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260317

**DATE AS OF CHANGE**: 20260317

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Drugs Made In America Acquisition II Corp.
- **CENTRAL INDEX KEY:** 0002040475
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42863
- **FILM NUMBER:** 26761627

**BUSINESS ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-870-3104

**MAIL ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d) of the**

**Securities Exchange Act of 1934**

**March 11, 2026**

Date of Report (Date of earliest event reported)

**Drugs Made In America Acquisition II Corp.**

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-42863** | **99-1815624** |
| (State or Other Jurisdiction <br> of Incorporation) | (Commission File Number) | (I.R.S. Employer <br> Identification Number) |

---

---

| | |
|:---|:---|
| **1 East Broward Boulevard, Suite 700**<br> **Fort Lauderdale, FL** | **33301** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**646-726-7074**

Registrant's telephone number, including area code:

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Units, each consisting of one Ordinary share, $0.0001 par value and one right to receive one-tenth of one ordinary share | DMIIU | The Nasdaq Stock Market LLC |
| Ordinary shares, par value $0.0001 per share | DMII | The Nasdaq Stock Market LLC |
| Rights, each entitling the holder to receive one-tenth of one Ordinary Share | DMIIR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 11, 2026, Drugs Made In America Acquisition II Corp. (the "**Company**") issued an unsecured convertible note (the "**Bridge Note**") to Alpha Multi Family Office (the "**Investor**") in the principal amount of $150,000 (the "**Bridge Loan**"). The Bridge Loan represents an initial loan towards a contemplated $1,400,000 financing (the "**Convertible Notes Financing**") pursuant to the Letter of Intent ("**LOI**") described under Item 8.01 of this Current Report on Form 8-K.

The Bridge Note has a maturity date nine months from the date of issuance, unless earlier converted or credited toward the definitive financing documents for the Convertible Notes Financing and does not bear interest. Upon the consummation of the Company's initial business combination (the "**Business Combination**"), the outstanding principal amount of the Bridge Note may, at the option of the Investor, be converted into shares of the combined entity at a conversion price equal to a 35% discount to the market price of such shares at the time of conversion.

The Company intends to use the proceeds of the Bridge Loan for accounting expenses, audit expenses and other expenses related to the Business Combination.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the issuance of the Bridge Note is incorporated herein by reference.

The Bridge Note represents a direct financial obligation of the Company. The Bridge Note is filed as Exhibit 10.3 hereto and is incorporated herein by reference.

**Item 8.01 Other Events**

On March 5, 2026, the Company entered into the LOI with the Investor relating to a proposed financing transaction pursuant to which the Investor indicated its intent to provide financing to the Company through a convertible note investment, subject to the negotiation and execution of definitive documentation. On March 9, 2026, the Company and the Investor entered into an addendum to the LOI which amended certain economic terms of the proposed financing (the "**Addendum**"). Pursuant to the LOI, as amended by the Addendum, the aggregate amount to be loaned is $1,400,000, of which the $150,000 paid to the Company pursuant to the Bridge Loan will be the first payment.

The remaining $1,250,000 of the proposed convertible notes financing is subject to the negotiation and execution of, a convertible note purchase agreement to be negotiated and finalized by the parties. The Addendum contemplates that $400,000 in aggregate funding will be disbursed to the Company on or prior to March 30, 2026.

The foregoing description of the LOI, Addendum and Bridge Note is not complete and is qualified in its entirety by reference to the full text of the LOI, Addendum and Bridge Note, copies of which are filed hereto as Exhibit 10.1, Exhibit 10.2 and Exhibit 10.3, respectively.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 10.1 | [Letter of Intent dated March 5, 2026 between Drugs Made in America Acquisition II Corp. and Alpha Multi Family Office](ea028195901ex10-1.htm) |
| 10.2 | [Addendum to Letter of Intent dated March 9, 2026](ea028195901ex10-2.htm) |
| 10.3 | [Bridge Financing Convertible Promissory Note dated March 11, 2026](ea028195901ex10-3.htm) |
| 104 | Cover Page Interactive Data File |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 17, 2026

---

| | |
|:---|:---|
| **DRUGS MADE IN AMERICA ACQUISITION II CORP.** | **DRUGS MADE IN AMERICA ACQUISITION II CORP.** |
| By: | /s/ Roger Bendelac |
| Name: | Roger Bendelac |
| Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**LETTER OF INTENT**

Effective Date: March 5th, 2026

From: Alpha Multi Family Office

9th Jabotinsky St. Bney Brak, Israel, Zip 5126418

To: S.E.E Capital Partners Ltd

2 Diagorou Street, 11th Floor, ERA House, Nicosia, Cyprus

RE: **<u>Proposed Senior Convertible Note Investment in Drugs Made in America<br> Acquisition Corp II (NASDAQ: DMIIU)</u>**

This Letter of Intent ("LOI") sets forth the preliminary understanding between Alpha Group Fund Management S.A. (the "Investor") and S.E.E Capital Partners Ltd. ("SEE Capital") regarding a proposed investment in Drugs Made in America Acquisition Corp II ("DMIIU"), a special purpose acquisition company listed on NASDAQ.

The proposed investment is intended to provide bridge financing to support the operations of DMIIU and facilitate the potential execution of a business combination transaction. The parties acknowledge that this LOI is intended to summarize the principal terms under discussion and, except for the provisions expressly stated to be binding, is non-binding and subject to the negotiation and execution of definitive agreements.

1. Investor

Alpha Multi Family Office, and/or any legal entity designated by it (collectively referred to as the "Investor").

2. Transaction Advisor

S.E.E Capital Partners Ltd., Nicosia, Cyprus ("SEE Capital"), shall act solely as transaction advisor and manager in connection with the proposed investment and potential merger transaction. SEE Capital shall not be deemed the sponsor or issuer of the Convertible Note.

**LETTER OF INTENT**

3. Investment Structure

The Investor intends to provide financing to DMIIU in the form of a Senior Convertible Note (the "Convertible Note").

The Convertible Note shall be convertible into discounted preferred equity shares of DMIIU or its successor entity, pursuant to terms to be defined in the definitive agreements.

4. Investment Amount

The total investment amount shall be USD $1,500,000 (the "Investment Amount").

The Investment Amount shall be deposited into an escrow account administered by a mutually agreed independent escrow agent, appointed by the Investor and approved by the Advisor, and released pursuant to the terms of the definitive Convertible Note Purchase Agreement.

5. Funding Schedule

The Investment Amount shall be disbursed pursuant to the terms of the definitive agreement that shall stipulate the operational and regulatory requirements of DMIIU, as agreed by the parties. Such terms shall include mechanism to disburse from the investment amount timely expense coverage required to maintain the listing of DMIIU pending any future merge transaction.

6. Conversion Mechanics

The Convertible Note shall be convertible upon the occurrence of one or more of the following events, subject to the terms of the definitive agreements:

(i) execution of a definitive business combination agreement by DMIIU;

(ii) closing of a business combination transaction;

(iii) restructuring of the sponsor entity or capital structure of DMIIU

7. Use of Funds

The proceeds of the Convertible Note may be used for SPAC operational expenses, regulatory filings, transaction preparation, and other expenses associated with pursuing a business combination.

**LETTER OF INTENT**

8. Due Diligence and Access to Information

Following execution of this LOI, the Investor and its advisors shall be granted reasonable access to relevant information relating to DMIIU for purposes of conducting legal, financial, and operational due diligence.

9. Failure to Complete Business Combination

If DMIIU does not complete a business combination within the applicable timeframe, the Convertible Note shall remain outstanding and shall be subject to repayment, conversion into alternative equity interests, or other mutually agreed consideration as may be defined in the definitive agreements.

10. Advisor Protection

In the event SEE Capital introduces or assists in identifying a merger target that results in a completed business combination transaction, the role and compensation of SEE Capital shall be recognized and documented in the definitive agreements related to such transaction.

11. Closing

Closing of the proposed investment shall occur upon execution of definitive agreements and satisfaction of customary closing conditions.

12. Confidentiality

All discussions and materials relating to the proposed investment shall remain confidential and shall not be disclosed to third parties except to advisors or as required by law.

13. Expenses

Each party shall bear its own legal, financial, and advisory costs associated with the negotiation of this LOI and any definitive agreements unless otherwise agreed.

**LETTER OF INTENT**

14. Exclusivity

Following execution of this LOI, the parties agree to negotiate exclusively regarding the proposed investment for a mutually agreed period, unless otherwise permitted by existing agreements.

15. Governing Law

This LOI shall be governed by the laws of the State of Israel and the exclusive jurisdiction rights are granted to the courts of Tel Aviv.

16. Non-Binding Nature

Except for the provisions relating to confidentiality, governing law, exclusivity, and expenses, this LOI is intended solely as a non-binding expression of interest.

17. Acceptance

If the foregoing terms are acceptable, please indicate agreement by signing below.

---

| | | | |
|:---|:---|:---|:---|
|  | INVESTOR | TRANSACTION ADVISOR | DMIIU |
| Signature | /s/ Alon Tal | /s/ Anastasio Carayannis | /s/ Roger Bendelac |
| Name | Alon Tal, ALPHA MULTI FAMILY OFFICE LTD | S.E.E. Capital Partners Ltd. | Roger Bendelac CEO |
| Title | Officer | Director | CEO |
| Date | March 05, 2026 | 06/03/2026 | March 6, 2026 |

---

## Exhibit 10.2

**Exhibit 10.2**

**ADDENDUM NO. 1 TO LETTER OF INTENT**

**ADDENDUM NO. 1**

**TO LETTER OF INTENT DATED MARCH 5, 2026**

Drugs Made in America Acquisition Corp II (NASDAQ: DMIIU)

Date: March 9, 2026

This Addendum modifies the Letter of Intent dated March 5, 2026 between:

**Alpha Multi Family Office** ("Investor")

**S.E.E Capital Partners Ltd.** ("Transaction Advisor")

and

**Drugs Made in America Acquisition Corp II ("Company").**

1. Acknowledgment of Letter of Intent

The parties acknowledge that on **March 5, 2026** the Company executed a Letter of Intent with the Investor relating to a proposed **Senior Convertible Note investment in the amount of $1,500,000**.

Except as modified herein, the **Letter of Intent remains in full force and effect.**

2. Modification of Aggregate Financing Amount

The parties agree that the **aggregate amount of financing to be provided to the Company shall be $1,400,000.**

The difference between the amount referenced in the LOI {$1,500,000) and the net investment to the Company {$1,400,000) **represents $100,000 in due diligence and negotiation costs associated with the Investor's advisor**.

3. Advisor Fee Responsibility

The parties acknowledge that **S.E.E Capital Partners Ltd. acts solely as advisor to the Investor.**

The **$100,000 advisory and due diligence cost shall be paid solely by the Investor to the Transaction Advisor.**

The Company **shall have no obligation, liability, or responsibility for such payment**, and the Investor alone shall be responsible for negotiating and settling such payment with the Transaction Advisor.

4. Interim Bridge Loan

The Investor shall provide an **initial bridge loan of $150,000** to the Company.

This amount shall constitute **a deposit toward the $1,400,000 aggregate financing** contemplated by the Letter of Intent as modified by this Addendum. The proceeds shall be used exclusively for:

● accounting expenses

● audit expenses

● reporting expenses

● regulatory compliance costs necessary to maintain the Company's listing and

● operations.

5. Conversion Rights

Any Convertible Note issued pursuant to this Addendum, including the **$150,000 Interim Convertible Note**, shall be **convertible solely at the discretion of the Investor.**

Conversion shall occur only **after completion of the Company's business combination (de-SPAC transaction).**

Upon such event, the Investor may elect to convert the outstanding principal amount into **shares of the post-merger combined entity.**

The conversion price shall reflect a **35% discount to the market value of the shares of the combined entity at the time of conversion.**

6. Remaining Financing

The remaining balance of the investment, **$1,250,000**, shall be issued pursuant to a **definitive Convertible Note Purchase Agreement reflecting the terms contemplated in the Letter of Intent as modified by this Addendum.**

The parties intend to negotiate and finalize the definitive agreement **during the current week.**

7. Escrow Arrangement

Upon execution of the definitive agreement, the **entire $1,400,000 financing amount shall be deposited into the IOLA escrow account of a licensed law firm mutually agreed upon by the Investor and the Company.**

Disbursements from such account shall require **joint authorization of both the Investor and the Company.**

8. Minimum Funding Milestone

The parties agree that **at least $400,000 in aggregate funding shall be disbursed to the Company on or prior to March 30, 2026.**

9. Interim Note Protection

The **$150,000 Interim Convertible Note shall not constitute an event of default prior to March 30, 2026**, provided the parties continue negotiating the definitive financing in good faith.

10. Governing Law

This Addendum and all interim financing instruments issued pursuant to it shall be governed by the **laws of the Cayman Islands. The Courts of the State of Israel can be used if an action is initiated by the lender, and the Courts of the State of New York can be used if a legal action is initiated by the borrower.**

---

| | |
|:---|:---|
| **Accepted and Agreed** | **Accepted and Agreed** |
| Alpha Multi Family Office | Alpha Multi Family Office |
| Signature: | /s/ Alon Tal |
| Name: | Alon Tal |
| Date: | March 10, 2026 |
| S.E.E Capital Partners Ltd. | S.E.E Capital Partners Ltd. |
| Signature: | /s/ Anastasio Carayannis |
| Name: | Anastasio Carayannis |
| Date: | March 10, 2026 |
| Drugs Made in America Acquisition Corp II | Drugs Made in America Acquisition Corp II |
| Roger E. Bendelac | Roger E. Bendelac |
| Chief Executive Officer | Chief Executive Officer |
| Signature: | /s/ Roger E. Bendelac |
| Date: | March 10, 2026 |

---

## Exhibit 10.3

**Exhibit 10.3**

**INTERIM CONVERTIBLE NOTE**

Issuer: Drugs Made in America Acquisition Corp II

**Principal Amount: $150,000**

Date: March 9, 2026

1. Purpose

This Interim Convertible Note represents bridge financing provided by the Investor to cover accounting, audit, and regulatory reporting expenses required for the Company to remain compliant.

2. Relationship to Main Financing

This note serves as a deposit toward the proposed $1,400,000 net financing outlined in the Letter of Intent dated March 5, 2026, and Addendum No. 1 dated March 9 2026.

3. Conversion

Conversion shall occur **solely at the discretion of the lender** after completion of the Company's business combination (**de-SPAC transaction**).

In the event of such occurrence, the outstanding principal amount may be converted into shares of the post-merger combined entity at a price reflecting a 35% discount to the market value of such shares at the time of conversion.

4. Maturity

This Note shall mature **nine (9) months from the date of issuance**, unless earlier converted or credited toward the definitive financing.

5. Governing Law

This Note shall be governed by the **laws of the Cayman Islands.**

**The Courts of the State of Israel in Tel Aviv can be used if the Defendant is the Borrower, and the Court of the State of New York, USA, can be used if the Defendant is the Lender.**

---

| | |
|:---|:---|
| **Signatures** |  |
| Investor Alon Tal, as signatory for | Investor Alon Tal, as signatory for |
| Tal Alpha Yezum Vekidum Asakim (2003) Ltd | Tal Alpha Yezum Vekidum Asakim (2003) Ltd |
| Signature: | /s/ Alon Tal |
| Date: | March 10, 2026 |
| Drugs Made in America Acquisition Corp II | Drugs Made in America Acquisition Corp II |
| Roger E. Bendelac | Roger E. Bendelac |
| Chief Executive Officer | Chief Executive Officer |
| Signature: | /s/ Roger E. Bendelac |
| Date: | March 10, 2026 |

---

The instrument is made effective upon credit of funds to the account of Drugs Made in America Acquisition Corp II

Corp II or for its benefit in the IOLA account of lawyer designated by Drugs Made in America Acquisition Corp II